---
title: "Madrigal Pharmaceuticals (MDGL) Gets a Buy from UBS"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293390160.md"
description: "UBS analyst Ashwani Verma maintained a Buy rating on Madrigal Pharmaceuticals (MDGL) with a $669 price target. This follows a Buy from Citizens JMP and contrasts with Bank of America's Hold rating."
datetime: "2026-07-21T21:49:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293390160.md)
  - [en](https://longbridge.com/en/news/293390160.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293390160.md)
---

# Madrigal Pharmaceuticals (MDGL) Gets a Buy from UBS

In a report released today, Ashwani Verma from UBS maintained a Buy rating on Madrigal Pharmaceuticals, with a price target of $669.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

According to TipRanks, Verma is a 4-star analyst with an average return of 13.5% and a 60.93% success rate. Verma covers the Healthcare sector, focusing on stocks such as Jazz Pharmaceuticals, Incyte, and Insmed.

In addition to UBS, Madrigal Pharmaceuticals also received a Buy from Citizens JMP’s Jonathan Wolleben in a report issued on July 17. However, on July 13, Bank of America Securities reiterated a Hold rating on Madrigal Pharmaceuticals (NASDAQ: MDGL).

### Related Stocks

- [MDGL.US](https://longbridge.com/en/quote/MDGL.US.md)
- [UBS.US](https://longbridge.com/en/quote/UBS.US.md)
- [JAZZ.US](https://longbridge.com/en/quote/JAZZ.US.md)
- [INCY.US](https://longbridge.com/en/quote/INCY.US.md)
- [INSM.US](https://longbridge.com/en/quote/INSM.US.md)

## Related News & Research

- [First Trust Advisors LP Sells 2,586 Shares of Madrigal Pharmaceuticals, Inc. $MDGL](https://longbridge.com/en/news/294471972.md)
- [Madrigal reports Q2 2026 Rezdiffra sales $364.3M; net loss $57.9M](https://longbridge.com/en/news/294353141.md)
- [Madrigal Pharmaceuticals President, CEO Sold Shares Worth Over $1.3M](https://longbridge.com/en/news/293269781.md)
- [Goldman Sachs Reaffirms Their Buy Rating on Amneal Pharmaceuticals (AMRX)](https://longbridge.com/en/news/293926120.md)
- [Madrigal Pharmaceuticals Q2 revenue rises 71% on Rezdiffra demand](https://longbridge.com/en/news/294353303.md)